🇺🇸 FDA
Patent

US 6410747

Highly selective butyrylcholinesterase inhibitors for the treatment and diagnosis of alzheimer's disease and dementias

expired A61KA61K31/40A61K31/407

Quick answer

US patent 6410747 (Highly selective butyrylcholinesterase inhibitors for the treatment and diagnosis of alzheimer's disease and dementias) held by The United States of America, as represented by the Department of Health and Human Services expires Mon Jun 20 2022 00:00:00 GMT+0000 (Coordinated Universal Time). Status: expired.

Key facts

Applicant
The United States of America, as represented by the Department of Health and Human Services
Grant date
Tue Jun 25 2002 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jun 20 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
6
CPC classes
A61K, A61K31/40, A61K31/407, A61P, A61P25/00